On Tuesday, shares of medical device company InVivo Therapeutics NVIV are gaining big, up almost 15% in afternoon trading on news that a patient in its INSPIRE study has significantly improved.
InVivo announced that a patient, who enrolled in its INSPIRE study back in December, has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury in the time between discharge and one-month evaluation.
This is the sixth out of the eleven patients-a 54.5% conversion rate-in follow-up to have had an AIS grade improvement. INSPIRE conversion rates are considerably higher than others.
"The AIS conversion rate observed thus far in the INSPIRE study has exceeded expectations," CEO and Chairman Mark Perrin said. "We look forward to following this patient's progress, and we're hopeful that we will continue to observe positive INSPIRE results as we work towards completing enrollment."
INSPIRE stands for In Vivo Study of Probable Benefit of the Neuro- Spi nal Scaffold™ for Safety and Neurologic Re covery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. It was designed to show the safety of the Neuro-Spinal Scaffold, one of InVivo's premier medical devices; it's an implant that is surgically placed following acute spinal cord injury.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.